This is a U.S. news story, published by CNBC, that relates primarily to Pfizer news.
For more U.S. news, you can click here:
more U.S. newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
cancer cachexia. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest experimental drug news, Pfizer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cancer treatmentsCNBC
•88% Informative
Patients with cancer cachexia saw improvements in body weight, muscle mass, quality of life and physical function, Pfizer says.
Results could pave the way for the drug, a monoclonal antibody called ponsegromab, to become the first treatment approved in the U.S. Cancer cachexia is a condition that causes cancer patients to lose their appetite and weight.
The condition affects about 9 million people worldwide.
VR Score
92
Informative language
93
Neutral language
84
Article tone
informal
Language
English
Language complexity
58
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links